FDA Plays

[hornettt]

Toys - RPTP has many near term cataysts

Raptor Pharmaceutical Corp. (NASDAQ: RPTP) is expected to release phase III results sometime in Q2 2011 for its lead drug, DR Cysteamine, for the treatment of nephropathic cystinosis. This is an inherited disease characterized by the accumulation of the amino acid cystine within cells, particularly damaging the eyes and kidneys. DR Cysteamine is a reformulation of the current best in care, Cystagon, which has several harsh side effects and an inconvenient four times a day dosage both of which can compromise the drugs effectiveness due to inability of the patients to comply with the dosing regimen.

Helpful link:
http://seekingalpha.com/article/261033-raptor-pharmaceuticals-pipeline-worth-a-closer-look?source=yahoo

Best of Wealth!